ClinicalTrials.gg
RecruitingNCT05636540Updated Feb 27, 2026

In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma

An Early Phase 1 interventional study of [18F]FluorThanatrace ([18F]FTT) in Pheochromocytoma and Paraganglioma, sponsored by Heather Wachtel. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Heather Wachtel · Early Phase 1, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Pheochromocytoma with a site in United States — 19 open to participants now, 28 under way, none of them phase 3. Pheochromocytoma · United States.

Planned enrollment
27th of 52
30 · median 31
Started
2023
with 1 other
Phase 1
13 of 69
6 open now
Primary completion
2026-12
later than 4 of 25 live
Registered
59th of 69
by date

Among the 69 studies in Pheochromocytoma with a site in United States, this one is the 27th largest by planned enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2023, is one of 13 in phase 1, reaches primary completion later than 4 of the 25 other live ones, and was the 59th registered.

Pheochromocytoma

158 studies on the registry are indexed under Pheochromocytoma; 57 are open to participants now.

Browse Pheochromocytoma studies →

Open to participants now

19 of the 69 studies in Pheochromocytoma with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Pheochromocytoma studies recruiting now, 22 (51%) set no upper age limit and 6 (14%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Pheochromocytoma with a site in United States, or all of them as a file.
02

Study summary

This study will enroll up to 30 evaluable patients with pheochromocytoma or paraganglioma who are undergoing surgical or systemic treatment.

A pre-treatment 18F-FluorThanatrace ([18F]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic therapy.

PET/CT imaging will be used to evaluate PARP-1 expression in sites of pheochromocytoma or paraganglioma using the investigational radiotracer [18F]FTT. This is an observational study in that [18F]FTT PET/CT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the [18F]FTT PET/CT results, treatment decisions will be made by the treating physicians based upon clinical criteria.

Read the detailed description

Up to 30 patients who will undergo approximately 60 minutes of dynamic scanning head to thigh starting at approximately the same time as the injection, this will be followed by a second head to thigh scan [starting at approximately 90 minutes post injection. PET/CT imaging sessions will include an injection of ≤ 12 mCi of [18F]FTT intravenously (approximate range for most studies is anticipated to be 8-12 mCi).

If surgery is performed according to standard of care tissue will be processed for both clinical and research use, if the subject has consented for use of tissue. Data will be collected to evaluate uptake of [18F]FTT in pheochromocytoma and paraganglioma and compare with PARP-1 activity and other experimental assays in tissue from biopsy and surgery, when available.

All evaluable patients may undergo surgery or systemic therapy following the [18F]FTT PET/CT scan. Up to 10 patients undergoing systemic therapy may undergo a second (optional) scan that will be performed approximately 1-21 days after therapy has started. The second scan is obtained to evaluate whether the initiation of systemic therapy alters [18F]FTT uptake. As this is a pilot study, only a limited number of patients are sought for the second scan.

03

Conditions studied

  • Pheochromocytoma
  • Paraganglioma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants will be ≥ 18 years of age.
  2. Clinical diagnosis of pheochromocytoma or paraganglioma based on biochemical and imaging studies At least one lesion identified on standard of care imaging (e.g. CT, MRI, FDG or 68-Gallium dotatate, other PET/CT or MIBG).
  3. Standard of care germline genetic testing performed for clinical purposes or participant's consent for germline genetic testing for research purposes.
  4. Participants must be informed of the nature of this study and be willing to provide written and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion criteria

Exclusion Criteria:

  1. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
  2. Females who are pregnant or breastfeeding will not be eligible for this study; a urine pregnancy test will be performed in women of prior to FTT injection.
  3. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Early Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cohort A

    After undergoing screening assessments and verifying eligibility for study participation subjects will be scheduled to undergo a baseline experimental \[18F\]FTT PET/CT scan prior to surgery. Patients in Cohort A will undergo surgery with or without additional therapy.

    Drug: [18F]FluorThanatrace ([18F]FTT)

  • Experimental
    Cohort B

    After undergoing screening assessments and verifying eligibility for study participation subjects will be scheduled to undergo a baseline experimental \[18F\]FTT PET/CT scan prior to systemic therapy with radionuclide or chemotherapy. Up to 10 patients undergoing systemic therapy may undergo a second (optional) scan that will be performed approximately 1-21 days after therapy has started. The second scan is obtained to evaluate whether the initiation of systemic therapy alters \[18F\]FTT uptake. As this is a pilot study, only a limited number of patients are sought for the second scan.

    Drug: [18F]FluorThanatrace ([18F]FTT)

Interventions

  • DrugFluorthanatrace F-18Studies of Fluorthanatrace F-18Fluorthanatrace F-18 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A pre-treatment 18F-FluorThanatrace (\[18F\]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic therapy.

06

What researchers measure

Primary outcomes

  1. Standard uptake value (SUV)measurement - [F18]FTT

    Qualitative measure SUV of \[18F\]FTT in phenochromocytoma/paraganlioma region (categories: positive, negative or mixed)

    Time frame: Baseline

  2. Maximum standard uptake value (SUV)measurement - [F18]FTT

    Measure of maximum SUV of \[18F}FTT in primary lesion region

    Time frame: Baseline

  3. Mean Standard uptake value (SUV)measurement - [F18]FTT

    Measure of mean SUV of \[18F}FTT in primary lesion region

    Time frame: Baseline

  4. Peak Standard uptake value (SUV)measurement - [F18]FTT

    Measure of peak SUV of \[18F}FTT in primary lesion region

    Time frame: Baseline

  5. Standard uptake value (SUV)measurement - [F18]FTT

    Qualitative measure SUV of \[18F\]FTT in phenochromocytoma/paraganlioma region (categories: positive, negative or mixed)

    Time frame: Follow-Up (1-21 days post therapy)

  6. Maximum standard uptake value (SUV)measurement - [F18]FTT

    Measure of maximum SUV of \[18F}FTT in primary lesion region

    Time frame: Follow-Up (1-21 days post therapy)

  7. Mean Standard uptake value (SUV)measurement - [F18]FTT

    Measure of mean SUV of \[18F}FTT in primary lesion region

    Time frame: Follow-Up (1-21 days post therapy)

  8. Peak Standard uptake value (SUV)measurement - [F18]FTT

    Measure of peak SUV of \[18F}FTT in primary lesion region

    Time frame: Follow-Up (1-21 days post therapy)

Other outcomes

  1. Progression free survival (PFS)

    Time from initial participation in study to disease progression or death from any cause,

    Time frame: From first day of treatment (PARP and/or ADT) to first documented disease progression or death due to any cause, assessed up to 10 years.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2022
First posted
Dec 5, 2022
StartActual
Jul 1, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05636540
Lead sponsor
Heather Wachtel
Responsible party
Heather Wachtel (Assistant Professor of Surgery, Abramson Cancer Center at Penn Medicine) — Sponsor-investigator
First posted
Dec 5, 2022
Start date
Jul 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 27, 2026

Study contacts

Heather Wachtel, MD
Contact
Heather.Wachtel@pennmedicine.upenn.edu
215-662-2341
Julia T Lewandowski
Contact
julia.lewandowski@pennmedicine.upenn.edu
215-662-2961
Heather Wachtel, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluorthanatrace F-18

Start the discussion